AxyS Pharmaceuticals Gains US Patents on Two Genes Linked to Disease

Dec 21, 1998

Premium

SOUTH SAN FRANCISCO, Calif.--AxyS Pharmaceuticals here last month received US patents on two proprietary genes, TULP 1 and TULP 2, that have been linked to two disease states. The disease linkages and details of some of the properties of TULP 1 are being published in the current issue of Nature Genetics, according to John Walker, AxyS's chairman and CEO. He declined further comment on the patents pending publication of the article.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Now You Can Read Them, Now You Can't

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

The Mouths of Heavy Drinkers Are Disgusting

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

For Health or For Fun?

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

This Week in Genome Research

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.

Jun

12

Featured Webinar

Bridging the Gap Between Testing and Treatment in Precision Oncology

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Main menu